Emyria Limited (ASX: EMD), a mental health care company, has announced its strategic acquisition of the Pax Centre, a renowned clinical service specializing in comprehensive psychological trauma care. This acquisition marks a significant milestone for Emyria's mission to expand and enhance mental health care. The company plans to establish a global Centre of Excellence that will focus on developing and delivering innovative and sustainable therapies, including psychedelic-assisted therapy.
By integrating the Emyria, Pax, and Emerald Clinics models, the company aims to unlock operational synergies and generate real-world data, strengthening its position in mental health care delivery and improving patient outcomes. Emyria also intends to accelerate patient recruitment and foster engagement with payers for its pivotal trial on MDMA-assisted therapy for post-traumatic stress disorder. Additionally, the company plans to expedite the development of psilocybin-assisted therapy protocols for treatment-resistant depression. An investor webinar explaining the acquisition and expected synergies is scheduled for Thursday, July 6th.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
